Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Bc0081a

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed1
Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT06773481Phase 1Recruiting

BC008-1A Injection for Recurrent CNS WHO G4 Glioma

NCT00285324CompletedPrimary

Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis

Showing all 2 trials

Research Network

Common Treatments

  • Bc0081a1

Active Sponsors

  • Beijing Tiantan Hospital1
  • National Institute of Neurological Disorders and Stroke (NINDS)1
  • Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.1

Top Investigators

Related Conditions

  • Glioma1
  • Glioblastomas Gbm1
  • Glioma Recurrent High Grade1
  • Primary Brain Tumor1
  • Radiation Necrosis1

Activity Timeline